

ICMJE DISCLOSURE FORM

Date: 2/27/2025

Your Name: Sirwan Darweesh

Manuscript Title: Het Parkinsoncoma: Passagère diepe bewustzijnsdalingen bij gevorderde Parkinson

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)												
Time frame: Since the initial planning of the work														
1	☒ None													
		Click the tab key to add additional rows.												
Time frame: past 36 months														
2	☐ None													
	<table border="1"> <tr> <td>2022-2025</td> <td>Veni Award [€280,000]. Netherlands Organisation for Health R&D.</td> </tr> <tr> <td>2022-2025</td> <td>Project: "Slow-SPEED UK" [\$250,000]. Parkinson's UK.</td> </tr> <tr> <td>2022-2025</td> <td>Project: "Slow-SPEED NL" [€500,000]. ParkinsonNL.</td> </tr> <tr> <td>2022-2025</td> <td>Project: "Slow-SPEED US" [\$50,000]. Davis Phinney Foundation.</td> </tr> <tr> <td>2022-2025</td> <td>Project: "Heterogeneity in Prodromal Parkinson's" [\$75,000]. Edmond J. Safra.</td> </tr> <tr> <td>2022-2025</td> <td>Project: "Prodromal Load" [\$250,000]. Michael J Fox Foundation.</td> </tr> </table>	2022-2025	Veni Award [€280,000]. Netherlands Organisation for Health R&D.	2022-2025	Project: "Slow-SPEED UK" [\$250,000]. Parkinson's UK.	2022-2025	Project: "Slow-SPEED NL" [€500,000]. ParkinsonNL.	2022-2025	Project: "Slow-SPEED US" [\$50,000]. Davis Phinney Foundation.	2022-2025	Project: "Heterogeneity in Prodromal Parkinson's" [\$75,000]. Edmond J. Safra.	2022-2025	Project: "Prodromal Load" [\$250,000]. Michael J Fox Foundation.	
2022-2025	Veni Award [€280,000]. Netherlands Organisation for Health R&D.													
2022-2025	Project: "Slow-SPEED UK" [\$250,000]. Parkinson's UK.													
2022-2025	Project: "Slow-SPEED NL" [€500,000]. ParkinsonNL.													
2022-2025	Project: "Slow-SPEED US" [\$50,000]. Davis Phinney Foundation.													
2022-2025	Project: "Heterogeneity in Prodromal Parkinson's" [\$75,000]. Edmond J. Safra.													
2022-2025	Project: "Prodromal Load" [\$250,000]. Michael J Fox Foundation.													
3	☒ None													

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
13	Other financial or non-financial interests	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.